Search

Acellular nerve allograft

Our team is working on the full update, which will be available soon. [L54673,L54668] … Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

Encainide

The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991. … Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack.

HGS-TR2J

HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.

Benzimate

It is currently under investigation by AmpliMed and is in phase I of clinical trial. … The anti-cancer and anti-viral activity of the benzimidazoles was originally investigated by the Proctor & Gamble Company beginning in the 1990's.

Dodecyltrimethylammonium

Calcium oxide

Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen

These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.

Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)

These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.

Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen

These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.

Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.